This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
As of today (2024-04-28), Clovis Oncology's share price is $0.015. Clovis Oncology's Median PS Value is $0.00. Therefore, Clovis Oncology's Price to Median PS Value for today is 0.00.
The historical rank and industry rank for Clovis Oncology's Median PS Value or its related term are showing as below:
CLVSQ's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.65 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
Clovis Oncology Median PS Value Historical Data
The historical data trend for Clovis Oncology's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Clovis Oncology's Median PS Value
For the Biotechnology subindustry, Clovis Oncology's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clovis Oncology's Price-to-Median-PS-Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Clovis Oncology's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Clovis Oncology's Price-to-Median-PS-Value falls into.
Clovis Oncology Median PS Value Calculation
Clovis Oncology's Median PS Value for today is calculated as
10-Year Median PS Ratio is 0.
Clovis Oncology's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.964.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clovis Oncology (OTCPK:CLVSQ) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Clovis Oncology's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
0.015
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clovis Oncology Median PS Value Related Terms
Thank you for viewing the detailed overview of Clovis Oncology's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Clovis Oncology (Clovis Oncology) Business Description
Clovis Oncology Inc is a biopharmaceutical company. It is focused on acquiring, developing, and commercializing anti-cancer agents in the United States, the EU, and additional international markets. The firm targets its development programs for the treatment of specific subsets of cancer populations. Its product candidate includes Rucaparib. Rucaparib is an oral small molecule inhibitor of poly ADP-ribose polymerase, is marketed in the United States for two indications specific to the recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. The company has two segments U.S and ex-U.S based on geograhic areas, with majority of its revenue coming from U.S.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CLVSQ has been successfully added to your 